77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Bibliographic Details
Main Authors: Yun Zhang, Xin Li, Hongming Pan, Yoon-Koo Kang, Chia-Jui Yen, Ming-Mo Hou, Kun-Ming Rau, Ying Yuan, Xiaopeng Ma, Xikun Wu, Jong-Seok Lee, Cunjing Yu, Katie Wood
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-535c95318305473282560c0ef50dded5
record_format Article
spelling doaj-535c95318305473282560c0ef50dded52020-12-11T10:05:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.007777 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)Yun Zhang0Xin Li1Hongming Pan2Yoon-Koo Kang3Chia-Jui Yen4Ming-Mo Hou5Kun-Ming Rau6Ying Yuan7Xiaopeng Ma8Xikun Wu9Jong-Seok Lee10Cunjing Yu11Katie Wood121 Clinical Medicine Department, Fujian Health College, Fuzhou, China 2 Department of Rheumatology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China Aff4 0000 0004 1759 700Xgrid.13402.34Sir Run Run Shaw Hospital, College of MedicineZhejiang University Hangzhou China Aff6 0000 0004 0533 4667grid.267370.7Asan Medical CenterUniversity of Ulsan College of Medicine Seoul South Korea 5 National Cheng Kung University Hospital, Tainan, Taiwan 9 Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan 13 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 4 The Cancer Institute Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, China 7Beigene (Beijing) Co., Ltd., Beijing, China6Beigene (Shanghai) Co., Ltd., Shanghai, China4National University Bundang Hospital, Seongnam-si, Korea, Republic of7BeiGene (Beijing) Co., Ltd., Beijing, China8BeiGene USA, Inc., San Mateo, CA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Yun Zhang
Xin Li
Hongming Pan
Yoon-Koo Kang
Chia-Jui Yen
Ming-Mo Hou
Kun-Ming Rau
Ying Yuan
Xiaopeng Ma
Xikun Wu
Jong-Seok Lee
Cunjing Yu
Katie Wood
spellingShingle Yun Zhang
Xin Li
Hongming Pan
Yoon-Koo Kang
Chia-Jui Yen
Ming-Mo Hou
Kun-Ming Rau
Ying Yuan
Xiaopeng Ma
Xikun Wu
Jong-Seok Lee
Cunjing Yu
Katie Wood
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Journal for ImmunoTherapy of Cancer
author_facet Yun Zhang
Xin Li
Hongming Pan
Yoon-Koo Kang
Chia-Jui Yen
Ming-Mo Hou
Kun-Ming Rau
Ying Yuan
Xiaopeng Ma
Xikun Wu
Jong-Seok Lee
Cunjing Yu
Katie Wood
author_sort Yun Zhang
title 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
title_short 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
title_full 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
title_fullStr 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
title_full_unstemmed 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
title_sort 77 association between programmed death-ligand 1 (pd-l1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (hcc)
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT yunzhang 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT xinli 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT hongmingpan 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT yoonkookang 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT chiajuiyen 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT mingmohou 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT kunmingrau 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT yingyuan 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT xiaopengma 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT xikunwu 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT jongseoklee 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT cunjingyu 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
AT katiewood 77associationbetweenprogrammeddeathligand1pdl1expressionandgenesignaturesofresponseorresistancetotislelizumabmonotherapyinhepatocellularcarcinomahcc
_version_ 1724386446594277376

Similar Items